Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01024335 · ClinicalTrials.gov registry record · Phase 2
Dronabinol Naltrexone Treatment for Opioid Dependence
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01024335 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 60 participants.
The verdict
NCT01024335, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We hypothesize that administering dronabinol during detoxification and during the first few weeks of naltrexone treatment will lead to improved naltrexone tolerability, resulting in better naltrexone compliance and treatment retention, and ultimately a reduction in opioid use and relapse rates.
Interventions
- DRUG injectable naltrexone and dronabinol
- DRUG Naltrexone and placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01024335
The ClinicalTrials.gov registry entry for NCT01024335 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which injectable naltrexone and dronabinol is the first listed.
NCT01024335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01024335 about?
NCT01024335 is a clinical study titled "Dronabinol Naltrexone Treatment for Opioid Dependence". The goal of this two-year study is to test the efficacy of dronabinol as an adjunct to maintenance treatment with naltrexone in opioid-dependent individuals. We hypothesize that administering dronabinol during detoxification and during the first few weeks of naltrexone treatment will lead to improve...
What is the current status of trial NCT01024335?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01024335?
The interventions under investigation include: injectable naltrexone and dronabinol (DRUG), Naltrexone and placebo (DRUG).
Who is sponsoring clinical trial NCT01024335?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.